Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Levodopa/carbidopa/entacapone
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Stalevo 100mg/25mg/200mg tablets
0409010X0BBABAB
|
Stalevo | Levodopa/carbidopa/entacapone | Central Nervous System | 6,247 |
|
Stalevo 150mg/37.5mg/200mg tablets
0409010X0BBACAC
|
Stalevo | Levodopa/carbidopa/entacapone | Central Nervous System | 5,102 |
|
Stalevo 125mg/31.25mg/200mg tablets
0409010X0BBAFAF
|
Stalevo | Levodopa/carbidopa/entacapone | Central Nervous System | 4,109 |
|
Stalevo 200mg/50mg/200mg tablets
0409010X0BBADAD
|
Stalevo | Levodopa/carbidopa/entacapone | Central Nervous System | 2,739 |
|
Stalevo 175mg/43.75mg/200mg tablets
0409010X0BBAGAG
|
Stalevo | Levodopa/carbidopa/entacapone | Central Nervous System | 1,942 |
|
Stanek 100mg/25mg/200mg tablets
0409010X0BDAFAB
|
Stanek | Levodopa/carbidopa/entacapone | Central Nervous System | 1,686 |
|
Sastravi 150mg/37.5mg/200mg tablets
0409010X0BCAEAC
|
Sastravi | Levodopa/carbidopa/entacapone | Central Nervous System | 1,565 |
|
Stalevo 75mg/18.75mg/200mg tablets
0409010X0BBAEAE
|
Stalevo | Levodopa/carbidopa/entacapone | Central Nervous System | 1,491 |
|
Sastravi 125mg/31.25mg/200mg tablets
0409010X0BCAAAF
|
Sastravi | Levodopa/carbidopa/entacapone | Central Nervous System | 1,434 |
|
Stanek 150mg/37.5mg/200mg tablets
0409010X0BDADAC
|
Stanek | Levodopa/carbidopa/entacapone | Central Nervous System | 1,280 |
|
Stanek 125mg/31.25mg/200mg tablets
0409010X0BDAGAF
|
Stanek | Levodopa/carbidopa/entacapone | Central Nervous System | 1,262 |
|
Sastravi 100mg/25mg/200mg tablets (Accord Healthcare Ltd)
0409010X0BCAHAB
|
Sastravi | Levodopa/carbidopa/entacapone | Central Nervous System | 1,133 |
|
Levodopa 150mg / Carbidopa 37.5mg / Entacapone 200mg tablets
0409010X0AAACAC
|
Levodopa/carbidopa/entacapone | Levodopa/carbidopa/entacapone | Central Nervous System | 978 |
|
Levodopa 100mg / Carbidopa 25mg / Entacapone 200mg tablets
0409010X0AAABAB
|
Levodopa/carbidopa/entacapone | Levodopa/carbidopa/entacapone | Central Nervous System | 898 |
|
Sastravi 200mg/50mg/200mg tablets
0409010X0BCAGAD
|
Sastravi | Levodopa/carbidopa/entacapone | Central Nervous System | 827 |
|
Stanek 200mg/50mg/200mg tablets
0409010X0BDABAD
|
Stanek | Levodopa/carbidopa/entacapone | Central Nervous System | 778 |
|
Stalevo 50mg/12.5mg/200mg tablets
0409010X0BBAAAA
|
Stalevo | Levodopa/carbidopa/entacapone | Central Nervous System | 761 |
|
Levodopa 125mg / Carbidopa 31.25mg / Entacapone 200mg tab
0409010X0AAAFAF
|
Levodopa/carbidopa/entacapone | Levodopa/carbidopa/entacapone | Central Nervous System | 721 |
|
Levodopa 200mg / Carbidopa 50mg / Entacapone 200mg tablets
0409010X0AAADAD
|
Levodopa/carbidopa/entacapone | Levodopa/carbidopa/entacapone | Central Nervous System | 506 |
|
Sastravi 175mg/43.75mg/200mg tablets (Accord Healthcare Ltd)
0409010X0BCAJAG
|
Sastravi | Levodopa/carbidopa/entacapone | Central Nervous System | 498 |
|
Stanek 75mg/18.75mg/200mg tablets
0409010X0BDAAAE
|
Stanek | Levodopa/carbidopa/entacapone | Central Nervous System | 455 |
|
Levodopa 175mg / Carbidopa 43.75mg / Entacapone 200mg tab
0409010X0AAAGAG
|
Levodopa/carbidopa/entacapone | Levodopa/carbidopa/entacapone | Central Nervous System | 447 |
|
Stanek 175mg/43.75mg/200mg tablets
0409010X0BDACAG
|
Stanek | Levodopa/carbidopa/entacapone | Central Nervous System | 445 |
|
Sastravi 75mg/18.75mg/200mg tablets
0409010X0BCACAE
|
Sastravi | Levodopa/carbidopa/entacapone | Central Nervous System | 410 |
|
Sastravi 100mg/25mg/200mg tablets (Actavis UK Ltd)
0409010X0BCADAB
|
Sastravi | Levodopa/carbidopa/entacapone | Central Nervous System | 366 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.